Chlormezanone in Anxiety : A Drug Rediscovered?
Abstract
The efficacy of chlormezanone, an infrequently prescribed minor tranquilizer, was tested in a six-week double-blind trial involving 154 anxious outpatients. The results showed that chlormezanone (800 mg./day) was significantly more effective than placebo and was equal in effectiveness to chlordiazepoxide (40 mg./day). Chlormezanone produced significantly more sedation and more side effects, but no more attrition, than chlordiazepoxide. Furtherstudies confirming these results could establish chlormezanone as a useful antianxiety agent.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).